NASDAQ:CMRX

Chimerix Competitors

$8.09
+0.18 (+2.28 %)
(As of 04/21/2021 02:25 PM ET)
Add
Compare
Today's Range
$7.73
Now: $8.09
$8.09
50-Day Range
$7.77
MA: $9.22
$10.61
52-Week Range
$1.37
Now: $8.09
$11.57
Volume10,896 shs
Average Volume1.13 million shs
Market Capitalization$693.14 million
P/E RatioN/A
Dividend YieldN/A
Beta1.88

Competitors

Chimerix (NASDAQ:CMRX) Vs. DCPH, CORT, ORGO, RCKT, FOLD, and GBT

Should you be buying CMRX stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Chimerix, including Deciphera Pharmaceuticals (DCPH), Corcept Therapeutics (CORT), Organogenesis (ORGO), Rocket Pharmaceuticals (RCKT), Amicus Therapeutics (FOLD), and Global Blood Therapeutics (GBT).

Deciphera Pharmaceuticals (NASDAQ:DCPH) and Chimerix (NASDAQ:CMRX) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, dividends, profitability, valuation, earnings, risk and institutional ownership.

Volatility & Risk

Deciphera Pharmaceuticals has a beta of 1.49, meaning that its share price is 49% more volatile than the S&P 500. Comparatively, Chimerix has a beta of 1.88, meaning that its share price is 88% more volatile than the S&P 500.

Institutional and Insider Ownership

73.6% of Deciphera Pharmaceuticals shares are owned by institutional investors. Comparatively, 45.4% of Chimerix shares are owned by institutional investors. 7.0% of Deciphera Pharmaceuticals shares are owned by insiders. Comparatively, 9.0% of Chimerix shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares Deciphera Pharmaceuticals and Chimerix's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Deciphera Pharmaceuticals$25 million104.72$-192,260,000.00($4.48)-10.14
Chimerix$12.52 million55.36$-112,580,000.00($0.86)-9.41

Chimerix has lower revenue, but higher earnings than Deciphera Pharmaceuticals. Deciphera Pharmaceuticals is trading at a lower price-to-earnings ratio than Chimerix, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Deciphera Pharmaceuticals and Chimerix, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Deciphera Pharmaceuticals03702.70
Chimerix00403.00

Deciphera Pharmaceuticals currently has a consensus target price of $70.30, indicating a potential upside of 54.74%. Chimerix has a consensus target price of $18.00, indicating a potential upside of 123.33%. Given Chimerix's stronger consensus rating and higher possible upside, analysts clearly believe Chimerix is more favorable than Deciphera Pharmaceuticals.

Profitability

This table compares Deciphera Pharmaceuticals and Chimerix's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Deciphera PharmaceuticalsN/A-45.02%-40.12%
Chimerix-321.31%-36.57%-33.53%

Summary

Chimerix beats Deciphera Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

Corcept Therapeutics (NASDAQ:CORT) and Chimerix (NASDAQ:CMRX) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, dividends, profitability, valuation, earnings, risk and institutional ownership.

Volatility & Risk

Corcept Therapeutics has a beta of 1.04, meaning that its share price is 4% more volatile than the S&P 500. Comparatively, Chimerix has a beta of 1.88, meaning that its share price is 88% more volatile than the S&P 500.

Institutional and Insider Ownership

75.4% of Corcept Therapeutics shares are owned by institutional investors. Comparatively, 45.4% of Chimerix shares are owned by institutional investors. 16.4% of Corcept Therapeutics shares are owned by insiders. Comparatively, 9.0% of Chimerix shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares Corcept Therapeutics and Chimerix's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Corcept Therapeutics$306.49 million8.81$94.18 million$0.7729.90
Chimerix$12.52 million55.36$-112,580,000.00($0.86)-9.41

Corcept Therapeutics has higher revenue and earnings than Chimerix. Chimerix is trading at a lower price-to-earnings ratio than Corcept Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Corcept Therapeutics and Chimerix, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Corcept Therapeutics01102.50
Chimerix00403.00

Corcept Therapeutics currently has a consensus target price of $24.00, indicating a potential upside of 4.44%. Chimerix has a consensus target price of $18.00, indicating a potential upside of 123.33%. Given Chimerix's stronger consensus rating and higher possible upside, analysts clearly believe Chimerix is more favorable than Corcept Therapeutics.

Profitability

This table compares Corcept Therapeutics and Chimerix's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Corcept Therapeutics30.73%25.38%23.16%
Chimerix-321.31%-36.57%-33.53%

Summary

Corcept Therapeutics beats Chimerix on 9 of the 14 factors compared between the two stocks.

Organogenesis (NASDAQ:ORGO) and Chimerix (NASDAQ:CMRX) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, dividends, profitability, valuation, earnings, risk and institutional ownership.

Volatility & Risk

Organogenesis has a beta of 1.84, meaning that its share price is 84% more volatile than the S&P 500. Comparatively, Chimerix has a beta of 1.88, meaning that its share price is 88% more volatile than the S&P 500.

Institutional and Insider Ownership

4.6% of Organogenesis shares are owned by institutional investors. Comparatively, 45.4% of Chimerix shares are owned by institutional investors. 57.2% of Organogenesis shares are owned by insiders. Comparatively, 9.0% of Chimerix shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Organogenesis and Chimerix's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Organogenesis-1.61%-10.03%-2.22%
Chimerix-321.31%-36.57%-33.53%

Analyst Recommendations

This is a breakdown of current ratings and target prices for Organogenesis and Chimerix, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Organogenesis00403.00
Chimerix00403.00

Organogenesis currently has a consensus target price of $16.50, indicating a potential downside of 22.21%. Chimerix has a consensus target price of $18.00, indicating a potential upside of 123.33%. Given Chimerix's higher possible upside, analysts clearly believe Chimerix is more favorable than Organogenesis.

Earnings and Valuation

This table compares Organogenesis and Chimerix's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Organogenesis$260.98 million10.40$-40,450,000.00($0.42)-50.50
Chimerix$12.52 million55.36$-112,580,000.00($0.86)-9.41

Organogenesis has higher revenue and earnings than Chimerix. Organogenesis is trading at a lower price-to-earnings ratio than Chimerix, indicating that it is currently the more affordable of the two stocks.

Summary

Organogenesis beats Chimerix on 7 of the 12 factors compared between the two stocks.

Chimerix (NASDAQ:CMRX) and Rocket Pharmaceuticals (NASDAQ:RCKT) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, earnings, valuation, institutional ownership and risk.

Insider & Institutional Ownership

45.4% of Chimerix shares are owned by institutional investors. 9.0% of Chimerix shares are owned by company insiders. Comparatively, 41.4% of Rocket Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Volatility and Risk

Chimerix has a beta of 1.88, suggesting that its share price is 88% more volatile than the S&P 500. Comparatively, Rocket Pharmaceuticals has a beta of 2.05, suggesting that its share price is 105% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Chimerix and Rocket Pharmaceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Chimerix00403.00
Rocket Pharmaceuticals011302.93

Chimerix currently has a consensus price target of $18.00, indicating a potential upside of 123.33%. Rocket Pharmaceuticals has a consensus price target of $59.1818, indicating a potential upside of 38.73%. Given Chimerix's stronger consensus rating and higher possible upside, equities analysts plainly believe Chimerix is more favorable than Rocket Pharmaceuticals.

Profitability

This table compares Chimerix and Rocket Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Chimerix-321.31%-36.57%-33.53%
Rocket PharmaceuticalsN/A-35.81%-27.52%

Earnings & Valuation

This table compares Chimerix and Rocket Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Chimerix$12.52 million55.36$-112,580,000.00($0.86)-9.41
Rocket PharmaceuticalsN/AN/A$-77,270,000.00($1.58)-27.18

Rocket Pharmaceuticals has lower revenue, but higher earnings than Chimerix. Rocket Pharmaceuticals is trading at a lower price-to-earnings ratio than Chimerix, indicating that it is currently the more affordable of the two stocks.

Summary

Rocket Pharmaceuticals beats Chimerix on 7 of the 13 factors compared between the two stocks.

Amicus Therapeutics (NASDAQ:FOLD) and Chimerix (NASDAQ:CMRX) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, earnings, risk, dividends, institutional ownership and profitability.

Volatility & Risk

Amicus Therapeutics has a beta of 1.57, indicating that its share price is 57% more volatile than the S&P 500. Comparatively, Chimerix has a beta of 1.88, indicating that its share price is 88% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings for Amicus Therapeutics and Chimerix, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Amicus Therapeutics07602.46
Chimerix00403.00

Amicus Therapeutics presently has a consensus price target of $20.0385, suggesting a potential upside of 102.82%. Chimerix has a consensus price target of $18.00, suggesting a potential upside of 123.33%. Given Chimerix's stronger consensus rating and higher probable upside, analysts clearly believe Chimerix is more favorable than Amicus Therapeutics.

Valuation and Earnings

This table compares Amicus Therapeutics and Chimerix's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Amicus Therapeutics$182.24 million14.34$-356,390,000.00($1.31)-7.55
Chimerix$12.52 million55.36$-112,580,000.00($0.86)-9.41

Chimerix has lower revenue, but higher earnings than Amicus Therapeutics. Chimerix is trading at a lower price-to-earnings ratio than Amicus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

45.4% of Chimerix shares are held by institutional investors. 2.5% of Amicus Therapeutics shares are held by insiders. Comparatively, 9.0% of Chimerix shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Amicus Therapeutics and Chimerix's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Amicus Therapeutics-120.18%-73.81%-36.10%
Chimerix-321.31%-36.57%-33.53%

Summary

Chimerix beats Amicus Therapeutics on 10 of the 14 factors compared between the two stocks.

Chimerix (NASDAQ:CMRX) and Global Blood Therapeutics (NASDAQ:GBT) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, risk, profitability, dividends, valuation, institutional ownership and earnings.

Risk & Volatility

Chimerix has a beta of 1.88, meaning that its stock price is 88% more volatile than the S&P 500. Comparatively, Global Blood Therapeutics has a beta of 1.39, meaning that its stock price is 39% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings and price targets for Chimerix and Global Blood Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Chimerix00403.00
Global Blood Therapeutics051402.74

Chimerix currently has a consensus target price of $18.00, suggesting a potential upside of 123.33%. Global Blood Therapeutics has a consensus target price of $90.3158, suggesting a potential upside of 115.45%. Given Chimerix's stronger consensus rating and higher probable upside, analysts clearly believe Chimerix is more favorable than Global Blood Therapeutics.

Valuation and Earnings

This table compares Chimerix and Global Blood Therapeutics' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Chimerix$12.52 million55.36$-112,580,000.00($0.86)-9.41
Global Blood Therapeutics$2.11 million1,239.61$-266,770,000.00($4.71)-8.93

Chimerix has higher revenue and earnings than Global Blood Therapeutics. Chimerix is trading at a lower price-to-earnings ratio than Global Blood Therapeutics, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

45.4% of Chimerix shares are owned by institutional investors. 9.0% of Chimerix shares are owned by company insiders. Comparatively, 4.3% of Global Blood Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Chimerix and Global Blood Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Chimerix-321.31%-36.57%-33.53%
Global Blood Therapeutics-332.94%-56.43%-39.32%

Summary

Chimerix beats Global Blood Therapeutics on 11 of the 14 factors compared between the two stocks.


Chimerix Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Deciphera Pharmaceuticals logo
DCPH
Deciphera Pharmaceuticals
1.6$45.43+1.0%$2.65 billion$25 million-9.09Analyst Revision
Corcept Therapeutics logo
CORT
Corcept Therapeutics
1.5$23.02+2.1%$2.64 billion$306.49 million25.87
Organogenesis logo
ORGO
Organogenesis
1.0$21.21+3.3%$2.62 billion$260.98 million-353.50News Coverage
Rocket Pharmaceuticals logo
RCKT
Rocket Pharmaceuticals
1.4$42.94+1.5%$2.61 billionN/A-23.59
Amicus Therapeutics logo
FOLD
Amicus Therapeutics
1.6$9.89+1.1%$2.59 billion$182.24 million-8.60Analyst Upgrade
Insider Selling
Global Blood Therapeutics logo
GBT
Global Blood Therapeutics
1.4$42.08+1.9%$2.57 billion$2.11 million-9.11Analyst Report
News Coverage
Intra-Cellular Therapies logo
ITCI
Intra-Cellular Therapies
1.7$29.62+3.2%$2.47 billion$60,000.00-9.20Analyst Revision
News Coverage
Ligand Pharmaceuticals logo
LGND
Ligand Pharmaceuticals
1.6$150.54+2.5%$2.44 billion$120.28 million-152.06Decrease in Short Interest
Xencor logo
XNCR
Xencor
1.2$42.07+1.3%$2.41 billion$156.70 million-30.05
Dicerna Pharmaceuticals logo
DRNA
Dicerna Pharmaceuticals
2.0$29.49+3.3%$2.32 billion$23.90 million-18.32Analyst Report
Insider Selling
Analyst Revision
News Coverage
Arcus Biosciences logo
RCUS
Arcus Biosciences
1.8$33.69+5.2%$2.26 billion$15 million-17.64
Cryoport logo
CYRX
Cryoport
1.7$51.74+4.1%$2.26 billion$33.94 million-89.21
Prestige Consumer Healthcare logo
PBH
Prestige Consumer Healthcare
1.6$45.74+1.3%$2.25 billion$963.01 million14.20
ALX Oncology logo
ALXO
ALX Oncology
1.9$55.92+2.6%$2.18 billionN/A0.00
Zentalis Pharmaceuticals logo
ZNTL
Zentalis Pharmaceuticals
1.4$53.01+3.5%$2.10 billionN/A0.00Analyst Report
Madrigal Pharmaceuticals logo
MDGL
Madrigal Pharmaceuticals
1.7$129.60+2.5%$2.02 billionN/A-11.71News Coverage
MacroGenics logo
MGNX
MacroGenics
1.2$33.87+0.6%$2.02 billion$64.19 million-10.82Analyst Report
Insider Selling
NGM Biopharmaceuticals logo
NGM
NGM Biopharmaceuticals
1.8$26.79+3.7%$1.98 billion$103.54 million-20.14
Amarin logo
AMRN
Amarin
1.6$5.03+1.6%$1.95 billion$429.76 million-100.58
Revance Therapeutics logo
RVNC
Revance Therapeutics
1.7$27.49+2.5%$1.91 billion$410,000.00-5.98
Axsome Therapeutics logo
AXSM
Axsome Therapeutics
1.4$53.71+5.7%$1.89 billionN/A-19.97Unusual Options Activity
News Coverage
FibroGen logo
FGEN
FibroGen
1.8$20.43+0.4%$1.87 billion$256.58 million-7.83
IGM Biosciences logo
IGMS
IGM Biosciences
1.7$58.22+0.4%$1.86 billionN/A-24.77
Kura Oncology logo
KURA
Kura Oncology
1.6$27.84+0.4%$1.85 billionN/A-17.08News Coverage
Cytokinetics logo
CYTK
Cytokinetics
1.7$25.37+0.3%$1.81 billion$26.87 million-13.28Analyst Report
Seres Therapeutics logo
MCRB
Seres Therapeutics
1.7$20.05+2.2%$1.79 billion$34.51 million-17.14
Pandion Therapeutics logo
PAND
Pandion Therapeutics
1.0$60.05+0.0%$1.77 billion$970,000.000.00
Five Prime Therapeutics logo
FPRX
Five Prime Therapeutics
1.4$38.00+0.0%$1.77 billion$14.87 million-14.18
MORF
Morphic
1.3$57.56+5.7%$1.76 billion$16.98 million-36.90Insider Selling
Gap Up
Ironwood Pharmaceuticals logo
IRWD
Ironwood Pharmaceuticals
1.6$10.80+1.3%$1.72 billion$428.41 million15.65Analyst Upgrade
Unusual Options Activity
News Coverage
Amneal Pharmaceuticals logo
AMRX
Amneal Pharmaceuticals
1.8$5.77+1.7%$1.70 billion$1.63 billion14.07
Generation Bio logo
GBIO
Generation Bio
1.8$30.81+2.3%$1.70 billionN/A0.00Gap Up
Heron Therapeutics logo
HRTX
Heron Therapeutics
1.7$18.10+1.8%$1.63 billion$145.97 million-7.33
Supernus Pharmaceuticals logo
SUPN
Supernus Pharmaceuticals
1.7$31.49+2.5%$1.62 billion$392.76 million13.07Analyst Upgrade
Myovant Sciences logo
MYOV
Myovant Sciences
1.3$18.95+5.8%$1.62 billionN/A-6.74Analyst Downgrade
Increase in Short Interest
ADC Therapeutics logo
ADCT
ADC Therapeutics
1.7$23.66+2.9%$1.58 billion$2.34 million-10.03
Harmony Biosciences logo
HRMY
Harmony Biosciences
1.4$27.82+1.4%$1.56 billionN/A0.00
Prelude Therapeutics logo
PRLD
Prelude Therapeutics
1.5$35.99+7.7%$1.55 billionN/A0.00Analyst Upgrade
News Coverage
Travere Therapeutics logo
TVTX
Travere Therapeutics
1.2$25.87+2.5%$1.52 billion$175.34 million-15.22Insider Selling
Aurinia Pharmaceuticals logo
AUPH
Aurinia Pharmaceuticals
1.8$12.34+3.8%$1.51 billion$320,000.00-8.39
uniQure logo
QURE
uniQure
1.7$32.19+1.0%$1.46 billion$7.28 million-8.54Unusual Options Activity
ImmunoGen logo
IMGN
ImmunoGen
1.5$7.49+2.3%$1.46 billion$82.27 million-18.27
Arcutis Biotherapeutics logo
ARQT
Arcutis Biotherapeutics
1.6$29.65+3.3%$1.44 billionN/A-3.21Analyst Upgrade
Gap Up
Keros Therapeutics logo
KROS
Keros Therapeutics
1.6$62.28+1.7%$1.43 billionN/A0.00
Theravance Biopharma logo
TBPH
Theravance Biopharma
1.6$22.25+0.8%$1.42 billion$73.41 million-4.70News Coverage
Applied Molecular Transport logo
AMTI
Applied Molecular Transport
2.0$40.85+2.7%$1.40 billionN/A0.00
PMV Pharmaceuticals logo
PMVP
PMV Pharmaceuticals
1.4$33.21+5.9%$1.40 billionN/A0.00Gap Down
Zealand Pharma A/S logo
ZEAL
Zealand Pharma A/S
1.2$31.89+0.5%$1.38 billion$6.20 million-13.99
Cara Therapeutics logo
CARA
Cara Therapeutics
1.6$28.25+2.7%$1.37 billion$19.89 million-13.33
Aclaris Therapeutics logo
ACRS
Aclaris Therapeutics
0.8$27.41+3.5%$1.37 billion$4.23 million-20.30Analyst Report
Increase in Short Interest
News Coverage
Gap Down
This page was last updated on 4/21/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.